Autres langues Tempus AI, Inc.

Actions

TEM

US88023B1035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 01/09/2026			Après clôture 00:43:57
62,27 ^USD	-1,24%		61,68	-0,96%

01/09	Tempus AI, Inc. : Piper Sandler passe de neutre à achat	ZM
24/08	Tempus AI reçoit le feu vert de la FDA pour son produit Tempus ECG-PH, une IA destinée à détecter les signes d'hypertension pulmonaire via des ECG standards	CI

Autres langues

01/09	Afternoon Meeting: La renta fija empaña el inicio de septiembre
01/09	Bonds spoil September's opening
01/09	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
24/08	Tempus AI Receives FDA Clearance For Tempus ECG-PH AI Product Intended To Detect Signs Of Pulmonary Hypertension From Standard ECGs
24/08	Tempus AI Gets FDA Clearance for AI-Enabled Pulmonary Hypertension Detector
24/08	Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
21/08	Tempus AI Insider Sold Shares Worth $2,038,723, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $6,577,840, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $2,696,444, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $1,542,674, According to a Recent SEC Filing
11/08	Tempus AI Insider Sold Shares Worth $1,000,800, According to a Recent SEC Filing
06/08	CellCarta Inc. And Tempus AI, Inc. Enter Strategic Collaboration For CDx Commercialization Lab Network
06/08	Tempus AI Insider Sold Shares Worth $1,100,076, According to a Recent SEC Filing
04/08	Tempus Ai, Inc. Announces Study Results Demonstrating Prism2 Multimodal Slide-Level Pathology Foundation Model Performance
04/08	Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
31/07	Tempus Ai Insider Sold Shares Worth $10,514,914, According to a Recent SEC Filing
30/07	Tempus AI, Inc. Revises Earnings Guidance for the Full Year 2026
30/07	Tempus AI Q2 Adjusted Loss Narrows, Revenue Rises
30/07	(TEM) Tempus AI Expects Full Year 2026 Revenue Range $1.595B - $1.605B, vs. FactSet Est of $1.59B
30/07	Tempus: Q2 Earnings Snapshot
30/07	Earnings Flash (TEM) Tempus AI, Inc. Reports Q2 Revenue $382.5M, vs. FactSet Est of $379.7M
30/07	Earnings Flash (TEM) Tempus AI, Inc. Posts Q2 Adjusted Loss $0.04 per Share, vs. FactSet Est of $-0.14
30/07	Tempus AI, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Tempus Reports Second Quarter 2026 Results
27/07	A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed